Covered recipient · General Payments record
WILLIAM D KEITH
Allopathic & Osteopathic Physicians Dermatology
General Payments · PY2019–2025
$4,100.18
- Reported across 169 records
- CMS publication 2026-06-30
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2025 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $326.77 | 16 |
By paying entity
PY2025 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $61.83 | 4 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $58.05 | 2 |
| UCB, Inc. | $50.74 | 2 |
| Incyte Corporation | $44.40 | 2 |
| Organon LLC | $37.32 | 3 |
| MERZ NORTH AMERICA, INC. | $29.21 | 1 |
| Galderma Laboratories, L.P. | $26.79 | 1 |
| GENZYME CORPORATION | $18.43 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2025 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Galderma Laboratories, L.P. | $26.79 | 02/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1234662213 | CMS |
| GENZYME CORPORATION | $18.43 | 12/02/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1233445339 | CMS |
| Incyte Corporation | $22.44 | 03/05/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1226069554 | CMS |
| Incyte Corporation | $21.96 | 07/16/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1226160128 | CMS |
| Lilly USA, LLC | $16.50 | 01/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186962670 | CMS |
| Lilly USA, LLC | $14.67 | 06/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186977150 | CMS |
| Lilly USA, LLC | $16.78 | 08/14/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186962668 | CMS |
| Lilly USA, LLC | $13.88 | 09/23/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1186977152 | CMS |
| MERZ NORTH AMERICA, INC. | $29.21 | 03/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1236973909 | CMS |
| Novartis Pharmaceuticals Corporation | $26.99 | 04/17/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1200317970 | CMS |
| Novartis Pharmaceuticals Corporation | $31.06 | 11/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1200263278 | CMS |
| Organon LLC | $15.93 | 01/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1237693310 | CMS |
| Organon LLC | $12.24 | 02/26/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1237693308 | CMS |
| Organon LLC | $9.15 | 03/19/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1237693306 | CMS |
| UCB, Inc. | $32.24 | 05/29/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1224616123 | CMS |
| UCB, Inc. | $18.50 | 06/25/2025 | Food and Beverage | Undisputed | 06/30/2026 | 1224616127 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.